CORT vs. EMA
CORT (Corcept Therapeutics Incorporated) and EMA (Emera Inc) are both stocks. CORT operates in Biotechnology (Healthcare), while EMA operates in Utilities - Regulated Electric (Utilities). Over the past year, CORT returned 5.36% vs 20.76% for EMA. At a correlation of -0.06, they often move in opposite directions.
Performance
CORT vs. EMA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CORT achieves a 110.72% return, which is significantly higher than EMA's 5.65% return.
CORT
- 1D
- 0.98%
- 1M
- 40.26%
- YTD
- 110.72%
- 6M
- -11.63%
- 1Y
- 5.36%
- 3Y*
- 46.50%
- 5Y*
- 27.35%
- 10Y*
- 29.33%
EMA
- 1D
- -1.29%
- 1M
- -2.87%
- YTD
- 5.65%
- 6M
- 10.36%
- 1Y
- 20.76%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
CORT vs. EMA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
CORT Corcept Therapeutics Incorporated | 110.72% | -54.69% |
EMA Emera Inc | 5.65% | 11.17% |
Correlation
The correlation between CORT and EMA is -0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.07 |
Correlation (All Time) Calculated using the full available price history since May 28, 2025 | -0.06 |
Fundamentals
CORT:
$7.66B
EMA:
$15.54B
CORT:
$0.41
EMA:
$3.55
CORT:
178.81
EMA:
14.37
CORT:
89.07
EMA:
0.46
CORT:
11.07
EMA:
1.79
CORT:
12.00
EMA:
1.69
CORT:
$769.10M
EMA:
$8.59B
CORT:
$755.64M
EMA:
$2.83B
CORT:
$3.66M
EMA:
$2.56B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CORT vs. EMA — Risk / Return Rank
CORT
EMA
CORT vs. EMA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and Emera Inc (EMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CORT | EMA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.47 | ||
| Sortino ratioReturn per unit of downside risk | -1.56 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 1.27 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 0.08 | 3.52 | -3.43 |
| Martin ratioReturn relative to average drawdown | 0.15 | 9.44 | -9.29 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CORT | EMA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.07 | 1.54 | -1.47 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.37 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.44 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.11 | 1.38 | -1.27 |
Drawdowns
CORT vs. EMA - Drawdown Comparison
The maximum CORT drawdown since its inception was -94.28%, which is greater than EMA's maximum drawdown of -5.93%. Use the drawdown chart below to compare losses from any high point for CORT and EMA.
Loading charts...
Drawdown Indicators
| CORT | EMA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.28% | -5.93% | -88.35% |
Max Drawdown (1Y)Largest decline over 1 year | -64.40% | -5.93% | -58.47% |
Max Drawdown (3Y)Largest decline over 3 years | -71.85% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -71.85% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -71.85% | — | — |
Current DrawdownCurrent decline from peak | -35.80% | -4.74% | -31.06% |
Average DrawdownAverage peak-to-trough decline | -53.44% | -1.76% | -51.68% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.34% | 2.20% | +33.14% |
Volatility
CORT vs. EMA - Volatility Comparison
Corcept Therapeutics Incorporated (CORT) has a higher volatility of 16.41% compared to Emera Inc (EMA) at 4.67%. This indicates that CORT's price experiences larger fluctuations and is considered to be riskier than EMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CORT | EMA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.41% | 4.67% | +11.74% |
Volatility (6M)Calculated over the trailing 6-month period | 85.07% | 10.21% | +74.86% |
Volatility (1Y)Calculated over the trailing 1-year period | 76.73% | 13.60% | +63.13% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 74.52% | 13.72% | +60.80% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 67.22% | 13.72% | +53.50% |
Dividends
CORT vs. EMA - Dividend Comparison
CORT has not paid dividends to shareholders, while EMA's dividend yield for the trailing twelve months is around 3.87%.
| Position | TTM | 2025 |
|---|---|---|
CORT Corcept Therapeutics Incorporated | 0.00% | 0.00% |
EMA Emera Inc | 3.87% | 2.12% |
Financials
CORT vs. EMA - Financials Comparison
This section allows you to compare key financial metrics between Corcept Therapeutics Incorporated and Emera Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CORT vs. EMA - Profitability Comparison
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.
EMA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Emera Inc reported a gross profit of 756.95M and revenue of 2.48B. Therefore, the gross margin over that period was 30.5%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.
EMA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Emera Inc reported an operating income of 626.62M and revenue of 2.48B, resulting in an operating margin of 25.3%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.
EMA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Emera Inc reported a net income of 583.50M and revenue of 2.48B, resulting in a net margin of 23.5%.
Frequently Asked Questions
CORT and EMA have a correlation of -0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CORT has higher volatility (16.41%) compared to EMA (4.67%). In terms of maximum drawdown, CORT dropped -94.28% vs EMA's -5.93%.
EMA currently has the higher Sharpe Ratio (1.54 vs 0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CORT and EMA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer